Nonalcoholic fatty liver disease in HIV-infected persons: Epidemiology and the role of nucleoside reverse transcriptase inhibitors

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 2, 2010, Pages 278-

  Guaraldi, Giovanni ^a   Stentarelli, Chiara ^a   Orlando, Gabriella ^a   Zona, Stefano ^a   Carli, Federica ^a   Ballestri, Stefano ^a   Lonardo, Amedeo ^a   Squillace, Nicola ^b   Loria, Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RNA DIRECTED DNA POLYMERASE INHIBITOR;

COMPUTER ASSISTED TOMOGRAPHY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADULT; BIOPSY; DRUG ADMINISTRATION SCHEDULE; FATTY LIVER; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 75649087345     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181c990ed     Document Type: Letter

References (5)

1. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50:464-473.
2. Lemoine M, Barbu V, Girard PM, et al. Altered hepatic expression of SREBP-1 and PPARgam-ma is associated with liver injury in insulin resistant lipodystrophic HIV-infected patients. AIDS. 2006;20:387-395.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
4. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47:250-257.
5. Iwasaki M, Takada Y, Hayashi M, et al. Non-invasive evaluation of graft steatosis in living donor liver transplantation. Transplantation. 2004;78:1501-1505. (Pubitemid 39552937)